Charles River Laboratories International (NYSE:CRL) Lowered to “Market Perform” Rating by William Blair

William Blair lowered shares of Charles River Laboratories International (NYSE:CRL) from an outperform rating to a market perform rating in a report released on Wednesday, Marketbeat Ratings reports. William Blair also issued estimates for Charles River Laboratories International’s FY2025 earnings at $9.40 EPS.

A number of other research analysts also recently commented on the stock. TD Cowen raised their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Finally, UBS Group reissued a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $209.00.

Charles River Laboratories International Trading Down 0.9 %

Shares of CRL opened at $168.27 on Wednesday. Charles River Laboratories International has a 1-year low of $160.85 and a 1-year high of $275.00. The company has a 50-day moving average of $187.81 and a 200 day moving average of $197.72. The firm has a market capitalization of $8.61 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 5.75 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same quarter last year, the business posted $2.72 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, research analysts expect that Charles River Laboratories International will post 10.18 EPS for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by insiders.

Institutional Trading of Charles River Laboratories International

Several large investors have recently bought and sold shares of the stock. KBC Group NV grew its position in Charles River Laboratories International by 0.9% during the 4th quarter. KBC Group NV now owns 85,362 shares of the medical research company’s stock worth $15,758,000 after purchasing an additional 796 shares during the last quarter. Blue Trust Inc. lifted its stake in Charles River Laboratories International by 7.8% during the 4th quarter. Blue Trust Inc. now owns 2,023 shares of the medical research company’s stock valued at $398,000 after acquiring an additional 146 shares during the period. Flagship Harbor Advisors LLC acquired a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $237,000. Veracity Capital LLC acquired a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $589,000. Finally, Mitchell & Pahl Private Wealth LLC lifted its stake in Charles River Laboratories International by 8.8% during the 4th quarter. Mitchell & Pahl Private Wealth LLC now owns 3,603 shares of the medical research company’s stock valued at $665,000 after acquiring an additional 292 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).